As of January 2018, the Food and Drug Administration (FDA) has approved nine biosimilars—highly similar copies of expensive biologic drugs used to treat cancer and other rare diseases—but only three ...

As several blockbuster drugs have faced patent challenges in recent years, many top drugmakers have pulled no punches in their opposition to the U.S. Patent and Trademark Office's inter partes review ...

NeXtGen is looking ahead to the expansion of its patent portfolio and product offerings. Future indications being explored include use in plastic surgery, orthopedic (tendon and bone), cardiovascular, ...

“Even if [inter partes reexamination] is not formally adversarial in the manner of inter partes review, it provides adequate adversarial participation for both the patent owner and requester, ...

Starting on September 16, 2012, on the first anniversary of the signing of the America Invents Act, the Patent Trial and Appeal Board (PTAB) was born. The jurisdiction of the PTAB is greatly expanded ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

The oral argument yesterday in Cuozzo Speed Technologies v. Lee did not clarify much about the case, but it did suggest that the Justices will not be composing a paean to the deftness of congressional ...

When someone creates a US patent, they go through a review process to stop the most blatant copies from previous patents or pre-existing work. After this, you may still have bad patents get through, ...

Policy makers in Washington are closer than ever to passing legislative reforms that have the potential to rein in the high cost of prescription drugs in the United States. Substantial obstacles ...